Estimating Demand for Potential Disease modifying Therapies for Alzheimer’s Disease in the UK

Abstract

AbstractBackgroundPhase three trials of the monoclonal antibodies lecanemab and donanemab, which target brain amyloid, have reported statistically significant differences in clinical endpoints in early Alzheimer’s disease. These drugs are already in use in some countries and are going through the regulatory approval process for use in the UK. Concerns have been raised about the ability of healthcare systems, including those in the UK, to deliver these treatments considering the resources required for their administration and monitoring.AimTo estimate the scale of real-world demand for monoclonal antibodies for AD in the United Kingdom.MethodWe used anonymised patient record databases from two National Health Service trusts for the year 2019 to collect clinical, demographic, cognitive and neuroimaging data for these cohorts. Eligibility for treatment was assessed using the inclusion criteria from the clinical trials of donanemab and lecanemab with consideration given to diagnosis, cognitive performance, cerebrovascular disease, and willingness to receive treatment.ResultsWe examined the records of 82,386 people referred to services covering some 2.2 million people. After applying the trial criteria, we estimate that a maximum of 906 people per year would start treatment with monoclonal antibodies in the two services, equating to 30,200 people if extrapolated nationally.ConclusionsMonoclonal antibody treatments for AD are likely to present a significant challenge for healthcare services to deliver in terms of the neuroimaging and treatment delivery. The data provided here allows health services to understand the potential demand and plan accordingly.